3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
2
Withdrawn
1
Unknown
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Prostatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tooth, Impacted
1
Testicular Neoplasms
1
Smoldering Multiple Myeloma
1
Oropharyngeal Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Hematologic Neoplasms
1
Hemangioma, Cavernous, Central Nervous System
1
Hemangioma, Cavernous
1
Ganglioneuroblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Esophageal Neoplasms
1
Epstein-Barr Virus Infections
1
Carcinoma, Renal Cell
1
Breast Carcinoma In Situ
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Carboplatin
6
Specimen Handling
5
Paclitaxel
5
Brachytherapy
5
Fluorodeoxyglucose F18
4
dostarlimab
3
atezolizumab
3
Trastuzumab
3
Radiation
3
Platinum
3
Nivolumab
3
Human Papillomavirus DNA Tests
3
Docetaxel
3
Colposcopy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tislelizumab
2
spartalizumab
2
olaparib
2
human papillomavirus vaccine, L1 type 16, 18
2
durvalumab
2
Vaccines
2
Surveys and Questionnaires
2
Standard of Care
2
Robotic Surgical Procedures
2
Radiotherapy, Intensity-Modulated
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Uterine Cervical Neoplasms
×
Watchful Waiting
×
Clear all
NCT06411938
2026-01-16
Merck-3
Indiana University
Phase NA
Active not recruiting
2,300 enrolled